Investigational drug · Phase 3
Plinabulin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
15
Any phase or sponsor naming "Plinabulin"
First trial start
2026
Dec 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Plinabulin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Non-squamous Non-Small Cell Lung Cance
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Plinabulin" as an intervention, largest first.
- Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLCPivotal-lookingCompleted
BeyondSpring Pharmaceuticals Inc.Industry
NCT02504489 · 559 participants · Start Dec 2015 · Primary completion Jul 21, 2021
Drug: Docetaxel + Plinabulin (DP); Docetaxel (D) · For: Non-Small Cell Lung Cancer
Sites: Chandler, Arizona; Anaheim, California; Whittier, California · 57 sites in all
- Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)Pivotal-lookingNot yet recruiting
BeyondSpring Pharmaceuticals Inc.Industry
NCT07361484 · 442 participants (planned) · Start Dec 1, 2026 · Primary completion Jun 1, 2029
Drug: Plinabulin; Docetaxel and 1 more · For: Non-Small Cell Lung Cancer; Non-squamous Non-Small Cell Lung Cance
- Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced NeutropeniaPivotal-lookingStatus unknown
BeyondSpring Pharmaceuticals Inc.Industry
NCT03294577 · 221 participants · Start Oct 23, 2019 · Primary completion Sep 25, 2020
Drug: Pegfilgrastim; Plinabulin and 1 more · For: Chemotherapy-induced Neutropenia
Sites: Hangzhou, China; Guangzhou, China; Harbin, China · 20 sites in all
- Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung CancerPivotal-lookingCompleted
Nereus Pharmaceuticals, Inc.Industry
NCT00630110 · 172 participants · Start Feb 2008 · Primary completion Jun 2011
Drug: docetaxel; NPI-2358 + docetaxel · For: Cancer
Sites: Scottsdale, Arizona; Encinitas, California; San Diego, California · 36 sites in all
- Plinabulin iv Solution in Prevention of TAC Induced NeutropeniaPivotal-lookingCompleted
BeyondSpring Pharmaceuticals Inc.Industry
NCT04227990 · 115 participants · Start Nov 27, 2017 · Primary completion Oct 15, 2018
Drug: Plinabulin; Pegfilgrastim and 1 more · For: Chemotherapy-induced Neutropenia
Sites: Guangzhou, China; Harbin, China; Shijiazhuang, China · 11 sites in all
- Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3Pivotal-lookingCompleted
BeyondSpring Pharmaceuticals Inc.Industry
NCT03102606 · 105 participants · Start May 29, 2018 · Primary completion Dec 12, 2018
Drug: Plinabulin; Pegfilgrastim · For: Chemotherapy-induced Neutropenia
Sites: Stanford, California; Skokie, Illinois; Louisville, Kentucky · 18 sites in all
BeyondSpring Pharmaceuticals Inc.Industry
NCT04345900 · 55 participants · Start Apr 5, 2017 · Primary completion Mar 20, 2018
Drug: Plinabulin; Pegfilgrastim · For: Chemotherapy-induced Neutropenia
Sites: Redlands, California; Orange City, Florida; Dublin, Georgia · 19 sites in all
- Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Active, not recruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT05599789 · 47 participants (planned) · Start Feb 1, 2023 · Primary completion May 21, 2025
Drug: Pembrolizumab in Combination with Plinabulin and Docetaxel · For: Non Small Cell Lung Cancer Metastatic
Sites: Beijing, China
Xiaorong DongAcademic, hospital or other
NCT05745350 · 45 participants (planned) · Start Mar 7, 2024 · Primary completion Jun 2025
Drug: Pembrolizumab, Plinabulin plus Etoposide and Platinum · For: Small Cell Lung Cancer Extensive Stage
Sites: Wuhan, China
Salma SabbourAcademic, hospital or other
NCT03575793 · 39 participants · Start Sep 6, 2018 · Primary completion Sep 25, 2023
Drug: Nivolumab; Plinabulin and 1 more · For: Lung Cancer; SCLC
Sites: Duarte, California; Tampa, Florida; Chicago, Illinois · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways.
Wang G, Wang S, Ding Z · J Med Chem 2026
- Dynamic microtubules as sensors in animal cells.
Mitchison TJ · Biophys J 2026
- Mechanism of Gzma-mediated GEF-H1 activation in intestinal epithelial cells leading to intestinal barrier dysfunction in sepsis.
Lin Z, Jiang H, Ni C, et al. · Clin Transl Med 2026
- Discovery of Novel Furan-type Phenylahistin Derivatives for Anticancer through P53-Mediated Mitochondrial Apoptosis and Microtubule Inhibition.
Wang S, Wang G, Chen N, et al. · ACS Med Chem Lett 2025
- Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers.
Lin SH, Subbiah V, Neri S, et al. · Med 2025
- Design, synthesis, and structure-activity relationship study of novel plinabulin derivatives as anti-tumor agents based on the co-crystal structure.
Wang S, Zhong C, Li F, et al. · Mol Divers 2025
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.